Iktos, a company specialized in Artificial Intelligence for new drug design, today announced that Kissei Pharmaceutical Co., Ltd. (“Kissei”), a Japanese pharmaceutical company with approximately 75 years of history, specialized in the field of urology, kidney-dialysis and unmet medical needs, has introduced Makya™, Iktos Software as a Service Platform for AI-driven drug discovery. This will enable the rapid and efficient design of new small molecules, leading to an increase in the speed of drug discovery and development.
Iktos’s AI technology, based on deep generative models and on a comprehensive data-driven chemical structure generation technology, helps to bring new insights and directions into the molecular discovery process and foster medicinal chemist’s productivity and acceleration of the identification of new drug candidates.
"Iktos has cutting-edge AI technology in small molecule drug discovery research, and their focus on further small molecule drug discovery technology development fits well with our strategy." said Yasuo Takehana, President and COO of Kissei. "We are very pleased that this collaboration will enhance our MedChem capabilities, create innovative compounds with competitive advantages, and lead to shorter compound discovery times."
“We are excited and proud to join forces with Kissei, a leading Japanese pharmaceutical company and to have their scientists use our software in their drug discovery projects", said Yann Gaston-Mathé, Co-founder and CEO of Iktos. “At Iktos, we strive to build an innovative technology platform capable of improving the efficiency of small molecule discovery by combining our powerful algorithmic technology, our know-how derived from the experience of the many collaborations we have established to date, and an intuitive and user-friendly user interface which is essential to an optimal user experience.”
Source: https://iktos.ai/